A review in Advances in Therapy warns that GLP-1 and GIP/GLP-1 receptor agonists, while driving weight loss, may reduce absolute protein intake in older adults and raise the risk of secondary sarcopenia. Randomized trials show liraglutide keeps protein at 13.9-17.5 percent of total energy, but…
A review published in the journal Advances in Therapy warns that GLP-1 and GIP/GLP-1 receptor agonist therapies , while effective at driving weight loss, may reduce absolute protein intake in older adults and thereby raise the risk of secondary sarcopenia . The warning matters because both drug classes are increasingly prescribed to older adults, a group in which type 2 diabetes and obesity frequently coexist with sarcopenia, a combination known as sarcopenic obesity .
Randomized trials show liraglutide preserves protein as a share of total energy intake at approximately 13.9-17.5%. The review argues that this proportional stability masks a real deficit: as total energy falls under caloric restriction, absolute protein intake falls with it. In older adults, whose muscles respond less readily to dietary protein, intake can drop below the level needed to adequately stimulate muscle protein synthesis .
Sarcopenia is not a benign outcome. It raises the risk of falls, fractures, disability, and mortality. The review does not claim incretin-induced muscle loss is proven. It claims something narrower and more actionable: the field has not adequately measured whether it happens.
The review's central finding is a split between relative and absolute protein intake. In randomized trials of liraglutide, protein contributed 13.9-17.5% of total energy during treatment. By that relative measure, the drug looks protein-neutral or even favorable. The review cautions against reading those numbers as reassurance, because the denominator is shrinking.
Appetite suppression, the mechanism that produces weight loss, is also the mechanism that threatens protein adequacy. Stronger appetite suppression drives total energy lower, and a stable percentage of a smaller total means fewer grams of protein per day. For individuals vulnerable to anabolic resistance , which includes most older adults, intake can fall below what is needed to maintain muscle. The review states the point directly: even when proportional protein intake is preserved, lower total energy intake can push absolute protein below the levels needed to adequately stimulate muscle protein synthesis.
The concern spans the incretin class. GLP-1 receptor agonists reduce calorie intake through central and gastrointestinal mechanisms; dual GIP/GLP-1 receptor agonists suppress appetite more strongly still. Because the review covers both classes, the warning applies across the incretin-based peptide portfolio, not just liraglutide.
The analysis is a narrative review , not a meta-analysis and not a new clinical trial. The authors evaluated available evidence on dietary protein intake during incretin-based therapy in older adults with type 2 diabetes and/or obesity treated with GLP-1 or GIP/GLP-1 receptor agonists. Five endpoint categories were the focus:
The results are notable mainly for what they do not establish. Randomized trials show the 13.9-17.5% protein share during liraglutide treatment. Missing is any systematic demonstration that intake changes translate into declines in muscle mass, strength, or physical performance. Few studies have evaluated that connection directly.
A narrative review can organize evidence, expose gaps, and generate hypotheses, but it cannot prove causation. The authors acknowledge the constraints: comprehensive data on dietary intake during incretin-based therapy remain limited; few studies have evaluated clinically meaningful muscle or functional outcomes; and longer-term trials with detailed dietary assessment, body composition analysis, and functional outcomes are lacking. The review is best read as a demand for measurement, not as a documented safety signal.
The arithmetic is simple; the physiology is not. Incretin-based therapies induce substantial weight loss through reduced calorie intake. GLP-1 receptor agonists slow gastric emptying, augment glucose-dependent insulin secretion, and dampen central appetite signals. Dual GIP/GLP-1 receptor agonists add GIP receptor modulation, and the review identifies stronger appetite suppression as the point where protein risk concentrates.
If an older patient cuts total energy by one third while protein stays at 15% of energy, absolute protein intake falls by one third. Percentage endpoints, which dominate the trial literature, cannot capture that loss. The deficit that would be trivial in a younger adult matters in old age because aging skeletal muscle is anabolically resistant: it requires a higher per-meal protein and leucine dose to produce the same muscle protein synthetic response.
The sarcopenia in question is secondary, not primary. It arises from disease, medication, reduced intake, and inactivity acting on aging muscle, rather than from aging alone. When type 2 diabetes and obesity already coexist with sarcopenia, producing sarcopenic obesity, drug-induced caloric restriction can push a vulnerable patient below the protein threshold for muscle maintenance. The review's core warning is that a weight loss success may carry a musculoskeletal cost that current trial designs do not measure.
Peptide Atlas registry data show the shape of the liraglutide evidence base. The drug has 239 registered clinical trials on file. The phase distribution is thin in later stages: Phase 2 accounts for 4 trials, Phase 4 for 2, and Phase 1 for 1. Nine trials are recruiting and 1 is active.
The notable registered trials show where the field's attention sits, and none of them is a muscle study:
The literature base points the same direction. Peptide Atlas indexes 154 PubMed papers for liraglutide. Recent contributions include a BMC Ophthalmology systematic review and meta-analysis on diabetic retinopathy progression with GLP-1 receptor agonists PMID 42380920 , a Journal of Anesthesia rat study of liraglutide and bupivacaine-induced sciatic nerve block PMID 42377486 , a Diabetologia paper on metabolic state and liraglutide effects on insulin secretion PMID 42350670 , a Nature Metabolism secondary analysis of the S-LiTE trial on exercise and liraglutide effects on vascular health and inflammation during weight loss maintenance PMID 42342869 , and an International Journal of Molecular Sciences systematic review on GLP-1 receptor agonists in non-alcoholic fatty liver disease PMID 42353331 . The Peptide Atlas reference page for liraglutide is at https://peptideatlas.co/peptides/liraglutide.
Glycemic control, vascular outcomes, retinopathy, hepatic fat, anesthesia pharmacology, and real-world weight loss dominate. Muscle mass does not appear as a primary outcome in the named portfolio. That distribution is the gap the review identifies: a drug class whose core mechanism is caloric restriction is studied organ by organ, but rarely for its effect on the tissue caloric restriction most directly threatens in older adults.
For clinicians, the actionable change is to treat protein intake as a monitored variable in older patients starting incretin therapy. Proportional protein intake is not adequate protein intake. A patient losing weight on liraglutide can be losing strength at the same time, so counseling should set absolute protein targets and resistance exercise should accompany pharmacologic weight loss. In patients with sarcopenic obesity, body composition and function matter as much as scale weight.
For researchers, the review defines a trial design agenda. Studies should pair detailed dietary assessment with body composition analysis and functional outcomes, including muscle strength and physical performance. The open question of whether dual GIP/GLP-1 receptor agonists carry higher sarcopenia risk than GLP-1 agonists alone argues for head-to-head trials that measure lean mass and protein intake, not only weight and glycemic control.
For the peptide development community, musculoskeletal safety is becoming a product attribute. Researchers developing and studying incretin-based peptide therapies will need to assess nutritional and musculoskeletal safety alongside glycemic and weight outcomes. The review identifies a critical evidence gap: whether reduced absolute protein intake during treatment leads to secondary sarcopenia in older adults. That gap should inform future trial designs and clinical monitoring. The review's conclusion is that a clearer understanding of protein adequacy and muscle health is needed to optimize weight management while minimizing secondary sarcopenia risk.
The review is explicit about its limits. Evidence on dietary intake changes is based on limited data. The link between reduced absolute protein intake and muscle health is inferred rather than directly demonstrated. And the authors call for longer-term trials before definitive conclusions can be drawn.
Four questions remain open:
Each question is answerable with the right design. Randomized trials of one to two years, with validated dietary records, DXA or MRI body composition assessment, and functional endpoints such as grip strength, gait speed, and chair stand performance, would determine whether the arithmetic of caloric restriction becomes clinical muscle loss. Comparative arms separating GLP-1 monotherapy from dual GIP/GLP-1 agonism would answer the class-specific question. Supplementation designs testing protein or leucine added to incretin therapy would begin to define minimum requirements. Until such studies report, the accurate summary is the review's own: weight loss is real, protein adequacy in older adults is under-measured, and the relationship between the two is unproven.
Peptides referenced: Liraglutide, GLP-1.
Related reading: Ac 2-26 preserves retinal neurons via FPR2-p38-NOX4 suppression, Illumina Beats Earnings as Director Meister Sells $140M in Shares, Semaglutide hsCRP cut of 37.8% in SELECT suggests anti-inflammatory role, FDA's Compounded GLP-1 Warning Letters and the Embody Telehealth Model.